Arkolith/Insider Trading/DAWN/Form 4

Bender Jeremy

CHIEF EXECUTIVE OFFICER, DirectorDay One Biopharmaceuticals, Inc. (DAWN) · full profile →Form 4 · filed Apr 23, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
17
7 non-derivative · 10 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 23, 2026Disposed to issuer(D)205K——0
Apr 23, 2026Disposed to issuer(D)20K——0
Apr 23, 2026Disposed to issuer(D)300K——0
Apr 23, 2026Disposed to issuer(D)148K——0
Apr 23, 2026Disposed to issuer(D)18K——0
Apr 23, 2026Disposed to issuer(D)300K——0
Apr 23, 2026Disposed to issuer(D)808K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 23, 2026Disposed to issuer(D)1.5M——0
Apr 23, 2026Disposed to issuer(D)397K——0
Apr 23, 2026Disposed to issuer(D)244K——0
Apr 23, 2026Disposed to issuer(D)286K——0
Apr 23, 2026Disposed to issuer(D)286K——0
Apr 23, 2026Disposed to issuer(D)355K——0
Apr 23, 2026Disposed to issuer(D)14K——0
Apr 23, 2026Disposed to issuer(D)82K——0
Apr 23, 2026Disposed to issuer(D)129K——0
Apr 23, 2026Disposed to issuer(D)222K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001863107-26-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML